Diabeloop today announced 12-month data supporting its hybrid closed-loop DBLG1 automated insulin delivery system. Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in … [Read More...] about Study backs automated insulin delivery system from Diabeloop
Main Content
Sponsored Content
Noble’s AdhereIT® Provides Flexibility of Design, Empowers Patients and Encourages Adherence
A recent study1 commissioned by Noble International analyzed the biologic initiation process and current gaps pertaining to patient guidance and self-injection training practices. Anecdotal evidence … [Read More...] about Noble’s AdhereIT® Provides Flexibility of Design, Empowers Patients and Encourages Adherence
Featured Posts
Better Therapeutics submits FDA de novo request for type 2 diabetes treatment
Better Therapeutics (Nasdaq:BTTX) announced today that it submitted a de novo classification request to the FDA for its BT-001 technology. San Francisco-based Better Therapeutics seeks marketing authorization for the BT-001 prescription digital … [Read More...] about Better Therapeutics submits FDA de novo request for type 2 diabetes treatment
JDRF launches Type 1 Diabetes Index simulation tool
JDRF announced today that it launched the Type 1 Diabetes Index (T1D Index) data simulation tool for measuring the impact of T1D around the globe. The tool measures the human and public health impact type 1 diabetes has in every country. JDRF said … [Read More...] about JDRF launches Type 1 Diabetes Index simulation tool
FDA approves Medtronic drug-eluting stents for treating bifurcation lesions
Medtronic (NYSE:MDT) announced today that the FDA approved its Onyx drug-eluting stents (DES) for treating certain lesions. Approval covers the treatment of non-left main bifurcation lesions utilizing the provisional bifurcation stenting … [Read More...] about FDA approves Medtronic drug-eluting stents for treating bifurcation lesions
Study backs automated insulin delivery system from Diabeloop
Diabeloop today announced 12-month data supporting its hybrid closed-loop DBLG1 automated insulin delivery system. Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in … [Read More...] about Study backs automated insulin delivery system from Diabeloop
Medtronic, FDA warn on potential cybersecurity risk with MiniMed insulin pump
Medtronic (NYSE:MDT) issued an urgent medical device correction notice to warn of potential issues with some MiniMed automated insulin delivery systems. The notice — dated this month — covers the company's MiniMed 600 series insulin pumps (MiniMed … [Read More...] about Medtronic, FDA warn on potential cybersecurity risk with MiniMed insulin pump
Vaxxas receives more than $5 million grant for vaccine delivery patch
Vaxxas announced today the Australian government is granting it nearly $5.5 million for the manufacturing of its vaccine delivery device. Cambridge, Massachusetts-based Vaxxas picked up AU$8.2 million ($5.48 million). The second-round grant … [Read More...] about Vaxxas receives more than $5 million grant for vaccine delivery patch
Study says Abbott FreeStyle Libre reduces rate of hospitalization
Abbott (NYSE:ABT) today announce real-world data demonstrating reductions in hospitalizations associated with the FreeStyle Libre system. The RELIEF study evaluated Abbott's FreeStyle Libre continuous glucose monitoring (CGM). The findings … [Read More...] about Study says Abbott FreeStyle Libre reduces rate of hospitalization
Insulet wins CE Mark for Omnipod 5 for children 2 and up
Insulet (Nasdaq:PODD) announced today that it received CE mark approval in Europe for its Omnipod 5 automated insulin delivery system. Insulet can now market Omnipod 5 in Europe for individuals 2 years and older with type 1 diabetes. Acton, … [Read More...] about Insulet wins CE Mark for Omnipod 5 for children 2 and up
Advanced NanoTherapies wins FDA breakthrough nod for drug-coated balloon
Advanced NanoTherapies announced today that it received FDA breakthrough device designation for its SirPlux Duo drug-coated balloon (DCB). Los Gatos, California-based Advanced NanoTherapies received the breakthrough nod for the use of the DCB in … [Read More...] about Advanced NanoTherapies wins FDA breakthrough nod for drug-coated balloon
Recall of Baxter Clearlink due to risk of leaks is Class I
The FDA announced today that the recall of the Clearlink basic solution set with Duovent from Baxter (NYSE:BAX) is Class I, the most serious kind. Clearkink with Duovent is part of a system for administering drugs and solutions to patients. Health … [Read More...] about Recall of Baxter Clearlink due to risk of leaks is Class I
In case you missed it
- Philip Morris hires two former FDA officials as it pushes ‘smoke-free’ development
- BD launches next-gen prefillable vaccine syringe
- Investors sue Medtronic over insulin pump problems
- FDA clears embolic microspheres from ABK Biomedical
- CISA warns on cybersecurity vulnerabilities for certain Baxter infusion pumps
- Lyra Therapeutics enrolls first patient in Phase 3 chronic rhinosinusitis trial
- Analysts see multi-year transition to growth for Embecta
- Phase 3 trial data support Glaukos iDose eye drop alternative
- Medtronic warns on Prevail Paclitaxel-coated PTCA balloon catheter
- WHO delivers insulin pens to Ukraine hospitals with support from Novo Nordisk
- Senseonics CFO is leaving
- Study backs next-gen Medtronic MiniMed 780G insulin pump
- Dexcom names Jake Leach chief operating officer
- FDA clears syringe infusion pump with Dose IQ software from Baxter
- FDA approves ‘first-in-market’ autoinjector for treating prolonged seizures
Clinical Trials
Study backs automated insulin delivery system from Diabeloop
Diabeloop today announced 12-month data supporting its hybrid closed-loop DBLG1 automated insulin delivery system. Paris-based Diabeloop evaluated DBLG1 in a large, multi-country patient cohort. Results demonstrated constant improvement in time in range and time in hypoglycemia remaining significantly low. The company said in a news release that the results, combined with trust in its algorithm, […]
Study says Abbott FreeStyle Libre reduces rate of hospitalization
Abbott (NYSE:ABT) today announce real-world data demonstrating reductions in hospitalizations associated with the FreeStyle Libre system. The RELIEF study evaluated Abbott’s FreeStyle Libre continuous glucose monitoring (CGM). The findings included the significant reduction of the rate of hospitalizations due to acute diabetes events (ADEs). This study evaluated people living with type 2 diabetes on once-daily […]
MedAlliance enrolls first patient in study of drug-eluting balloon for treating erectile dysfunction
MedAlliance announced today that it enrolled the first patient in a trial for its drug-eluting ballon in treating erectile dysfunction. Geneva, Switzerland-based MedAlliance said an 82-year-old Taiwanese man enrolled in the initial trial. It will evaluate the Selution SLR sirolimus-eluting balloon for the treatment of erectile dysfunction (ED). The Perfect-Selution FIM study includes 54 patients. […]
Lyra Therapeutics enrolls first patient in Phase 3 chronic rhinosinusitis trial
Lyra Therapeutics (Nasdaq:LYRA) announced today that it enrolled the first patient in its Phase 3 Enlighten II clinical trial. Enlighten II is evaluating the company’s LYR-210 in adult patients with chronic rhinosinusitis (CRS). Lyra’s proprietary XTreo platform delivers LYR-210. Watertown, Massachusetts-based Lyra designed the proprietary XTreo platform for precise, sustained and local delivery. The platform […]
Phase 3 trial data support Glaukos iDose eye drop alternative
Glaukos (NYSE:GKOS) today announced positive outcomes from two Phase 3 pivotal trials for its iDose TR system. iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce intraocular pressure (IOP). Glaukos designed it to continuously release therapeutic levels of medication for at least one year. Once all travoprost is released, iDose […]
